Ask HopeStage to review this study with me
Study ID: NCT07084831. We help you review the study, but cannot decide medical eligibility.
Not Yet RecruitingNCT07084831
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in adults with Schizophrenia
This study is not yet recruiting in Belgium, in Austria, in Czech Republic, .... It focuses on schizophrenia.
Schizophrenia, Cognitive ImpairmentDrugFrom 18 Years to 55 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Austria, Belgium, Czech Republic.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Medical University Innsbruck, UPC KU Leuven, and National Institute of Mental Health in Klecany. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include pregnancy or breastfeeding and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateEstimated: January 1, 2027
- Recruitment status
- Not Yet Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- European Group for Research In Schizophrenia
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Belgium, Austria, Czech Republic, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07084831
- Official title
- A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT07084831. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Austria.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by European Group for Research In Schizophrenia, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Not Yet RecruitingNCT07252752
Dopamine and Insulin in Psychosis
This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Austria.
Not Yet RecruitingNCT06778564
Stratification and Treatment in Early Psychosis Study - ENHANCE
This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Austria, Germany, Greece, Israel, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
Not Yet RecruitingNCT07434973
Stratification and Treatment in Early Psychosis Study - PROMOTE
This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Austria, Canada, Finland, Germany, Greece, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.